| scholarly article | Q13442814 |
| P50 | author | Marc Steben | Q42172208 |
| Suzanne Marie Garland | Q87258284 | ||
| Cosette M Wheeler | Q87723651 | ||
| Jorma Paavonen | Q88733900 | ||
| Laura Koutsky | Q111548098 | ||
| P2093 | author name string | Mauricio Hernandez-Avila | |
| Daron G Ferris | |||
| Elmar A Joura | |||
| Gonzalo Perez | |||
| Heather L Sings | |||
| Mark T Esser | |||
| Diane M Harper | |||
| Frank J Taddeo | |||
| Ronald W Jones | |||
| Eliav Barr | |||
| Sepp Leodolter | |||
| John W Boslego | |||
| Janine Bryan | |||
| Carlos Sattler | |||
| Grace W K Tang | |||
| Micki Nelson | |||
| Oliver M Bautista | |||
| P2860 | cites work | Imiquimod | Q35122733 |
| Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published patients | Q36111452 | ||
| Genital human papillomavirus infection in men. | Q36353396 | ||
| High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up | Q36612475 | ||
| Vulvar intraepithelial neoplasia: long term follow up of treated and untreated women. | Q36798327 | ||
| A population-based study of squamous cell vaginal cancer: HPV and cofactors | Q38458043 | ||
| Integration of HPV-16 and HPV-18 DNA in vulvar intraepithelial neoplasia | Q40348998 | ||
| Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. | Q40450678 | ||
| Natural history of vaginal intraepithelial neoplasia | Q45736749 | ||
| Preliminary results of 5% imiquimod cream in the primary treatment of vulva intraepithelial neoplasia grade 2/3. | Q46928170 | ||
| In situ and invasive vulvar cancer incidence trends (1973 to 1987) | Q53846013 | ||
| Effect of human papillomavirus vaccines on vulvar, vaginal, and anal intraepithelial lesions and vulvar cancer. | Q54569323 | ||
| The distribution of low and high-risk HPV types in vulvar and vaginal intraepithelial neoplasia (VIN and VaIN). | Q54570190 | ||
| High-risk human papillomavirus infection of the genital tract of women with a previous history or current high-grade vulvar intraepithelial neoplasia | Q57089413 | ||
| Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia | Q60441062 | ||
| Cervical intraepithelial neoplasia III: long-term outcome after cold-knife conization with clear margins | Q73588830 | ||
| Trends in squamous cell carcinoma of the vulva: the influence of vulvar intraepithelial neoplasia | Q73645484 | ||
| Cofactors with human papillomavirus in a population-based study of vulvar cancer | Q73804650 | ||
| Cervical intraepithelial neoplasia III: long-term follow-up after cold-knife conization with involved margins | Q77556318 | ||
| Detection of specific human papillomavirus types in paraffin-embedded sections of cervical carcinomas | Q81508004 | ||
| Trends in the incidence of invasive and in situ vulvar carcinoma | Q24825208 | ||
| Clinical features and risk of recurrence among patients with vaginal intraepithelial neoplasia | Q28199145 | ||
| Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women | Q28271727 | ||
| Evaluation of different treatment modalities for vulvar intraepithelial neoplasia (VIN): CO(2) laser vaporization, photodynamic therapy, excision and vulvectomy | Q28272759 | ||
| Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions | Q28301685 | ||
| Epidemiologic classification of human papillomavirus types associated with cervical cancer | Q29616213 | ||
| Chapter 28: Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries | Q30230410 | ||
| Epidemiology, diagnosis and treatment of vulvar intraepithelial neoplasia | Q31035514 | ||
| External genital warts: diagnosis, treatment, and prevention. | Q31112715 | ||
| Vulvar intraepithelial neoplasia: aspects of the natural history and outcome in 405 women | Q33228223 | ||
| Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18 | Q33910699 | ||
| Spontaneous regression of vulvar intraepithelial neoplasia 2-3. | Q34014775 | ||
| Risk of cervical and other cancers after treatment of cervical intraepithelial neoplasia: retrospective cohort study | Q34137284 | ||
| Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial | Q34415030 | ||
| Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases | Q34627305 | ||
| P433 | issue | 9574 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vaccine | Q134808 |
| P304 | page(s) | 1693-1702 | |
| P577 | publication date | 2007-05-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials | |
| P478 | volume | 369 |
| Q33772320 | "Knowledge and attitudes of Spanish adolescent girls towards human papillomavirus infection: where to intervene to improve vaccination coverage". |
| Q36681143 | "Saving lives": Adapting and adopting Human Papilloma Virus (HPV) vaccination in Austria |
| Q54439689 | 2016 European guideline for the management of vulval conditions. |
| Q38586257 | 9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV. |
| Q37641117 | A clinical and pathological overview of vulvar condyloma acuminatum, intraepithelial neoplasia, and squamous cell carcinoma |
| Q35724932 | A cost-utility analysis of cervical cancer screening and human papillomavirus vaccination in the Philippines |
| Q33573346 | A population-based evaluation of a publicly funded, school-based HPV vaccine program in British Columbia, Canada: parental factors associated with HPV vaccine receipt |
| Q33621078 | A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge |
| Q45368392 | A survey on the prevalence of high-risk subtypes of human papilloma virus among women with cervical neoplasia in Isfahan University of Medical Science. |
| Q34439784 | Adherence to the HPV vaccine dosing intervals and factors associated with completion of 3 doses |
| Q37222480 | Age for HPV vaccination |
| Q40628968 | An estimate of the public health impact and cost-effectiveness of universal vaccination with a 9-valent HPV vaccine in Germany |
| Q33725133 | An oral versus intranasal prime/boost regimen using attenuated human rotavirus or VP2 and VP6 virus-like particles with immunostimulating complexes influences protection and antibody-secreting cell responses to rotavirus in a neonatal gnotobiotic pi |
| Q37792174 | An overview of human papillomavirus infection for the dermatologist: disease, diagnosis, management, and prevention |
| Q37073522 | An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results |
| Q30534669 | Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels |
| Q43168107 | Antibody response to human papillomavirus vaccination and natural exposure in individuals with Fanconi Anemia |
| Q37802640 | Approaches to monitoring biological outcomes for HPV vaccination: challenges of early adopter countries. |
| Q27692056 | Are the currently existing anti-human papillomavirus vaccines appropriate for the developing world? |
| Q28088322 | Are we missing an opportunity for cancer prevention? Human papillomavirus vaccination for survivors of pediatric and young adult cancers |
| Q37715865 | Assessing the need for and acceptability of a free-of-charge postpartum HPV vaccination program |
| Q37346177 | Association of human papillomavirus with vulvar and vaginal intraepithelial disease: opportunities for prevention |
| Q36330260 | Awareness and acceptance of human papillomavirus vaccination among health sciences students in Malaysia |
| Q36112309 | Barriers to HPV immunization among blacks and latinos: a qualitative analysis of caregivers, adolescents, and providers |
| Q37802641 | Benefits of vaccinating young adult women with a prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine |
| Q81583241 | Brachial plexus neuritis following HPV vaccination |
| Q39933213 | CD4+ T helper cell responses against human bocavirus viral protein 2 viruslike particles in healthy adults |
| Q33640368 | CD4+ and CD8+ T cells can act separately in tumour rejection after immunization with murine pneumotropic virus chimeric Her2/neu virus-like particles |
| Q42240209 | CDC grand rounds: Reducing the burden of HPV-associated cancer and disease |
| Q28743261 | Capsomer vaccines protect mice from vaginal challenge with human papillomavirus |
| Q42255129 | Carcinogenic HPV prevalence and age-specific type distribution in 40,382 women with normal cervical cytology, ASCUS/LSIL, HSIL, or cervical cancer: what is the potential for prevention? |
| Q84582278 | Cervical cancer and vaccination--an overview |
| Q38748682 | Cervical cancer: A comprehensive approach towards extermination |
| Q34354553 | Cervical human papillomavirus infection among young women engaged in sex work in Phnom Penh, Cambodia: prevalence, genotypes, risk factors and association with HIV infection. |
| Q44453770 | Characterization of sociodemographic and clinicopathological features in Brazilian patients with vulvar squamous cell carcinoma. |
| Q35732867 | Clinical presentation, treatment and outcome of vaginal intraepithelial neoplasia |
| Q38124060 | Combination of adjuvants: the future of vaccine design |
| Q35235306 | Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model |
| Q36256554 | Comparison of HPV prevalence between HPV-vaccinated and non-vaccinated young adult women (20-26 years). |
| Q36916185 | Correlates of Human Papillomavirus Vaccine Completion Among Adolescent Girl Initiators |
| Q45189964 | Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: the potential impact of different cross-protection profiles. |
| Q33892348 | Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy. |
| Q49137840 | Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium |
| Q53281399 | Cost-effectiveness of a cervical screening program with human papillomavirus vaccine. |
| Q36618532 | Cost-effectiveness of vaccination with a quadrivalent HPV vaccine in Germany using a dynamic transmission model |
| Q37798010 | Cost–effectiveness of catch-up programs in human papillomavirus vaccination |
| Q37744987 | Current controversies in the USA regarding vaccine safety |
| Q34220545 | Current issues facing the introduction of human papillomavirus vaccine in malaysia |
| Q37640113 | Currently approved prophylactic HPV vaccines |
| Q58112353 | Dengue-2 virus-like particle (VLP) based vaccine elicits the highest titers of neutralizing antibodies when produced at reduced temperature |
| Q44093171 | Descriptive epidemiology of vaginal cancer incidence and survival by race, ethnicity, and age in the United States |
| Q39173880 | Development of an autologous canine cancer vaccine system for resectable malignant tumors in dogs |
| Q37272218 | Diagnosis and management of anal cancer. |
| Q33777098 | Distribution of genital wart human papillomavirus genotypes in China: a multi-center study |
| Q36194955 | EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease |
| Q39241147 | Ecological validity of cost-effectiveness models of universal HPV vaccination: A systematic literature review |
| Q36818045 | Economic evaluation of human papillomavirus vaccination in the United Kingdom |
| Q40207173 | Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials |
| Q34291064 | Effect of the decision-making process in the family on HPV vaccination rates among adolescents 9-17 years of age. |
| Q34210255 | Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data |
| Q38231641 | Effectiveness of individual-focused interventions to prevent chronic disease |
| Q64124343 | Efficacy, safety, and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine: An interim analysis of a randomized clinical trial |
| Q56967486 | Emerging human papillomavirus vaccines |
| Q35195399 | Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions |
| Q35991580 | Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria |
| Q35141381 | Ethical considerations of universal vaccination against human papilloma virus |
| Q34986037 | Evaluating the impact of human papillomavirus vaccines |
| Q35032369 | Financial incentives for increasing uptake of HPV vaccinations: a randomized controlled trial |
| Q82355557 | For debate: that Australia should consider changing to the bivalent vaccine |
| Q28750269 | Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial |
| Q34275134 | Fusion of CTLA-4 with HPV16 E7 and E6 enhanced the potency of therapeutic HPV DNA vaccine |
| Q36011666 | Geospatial patterns of human papillomavirus vaccine uptake in Minnesota. |
| Q37066141 | Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention |
| Q33703136 | Guillain–Barré syndrome after Gardasil vaccination: Data from Vaccine Adverse Event Reporting System 2006–2009 |
| Q51961251 | HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. |
| Q36774457 | HPV genotypes in paraffin sections of non-cervical squamous cell carcinoma in Qingdao of China |
| Q40051720 | HPV prevalence in vulvar cancer in Austria |
| Q37135183 | HPV vaccination for MSM: Synthesis of the evidence and recommendations from the Québec Immunization Committee |
| Q37410888 | HPV vaccination: the beginning of the end of cervical cancer? - A Review. |
| Q37687426 | HPV vaccine: Cervarix |
| Q56959368 | HPV vaccines and the prevention of cervical cancer |
| Q36793586 | HPV vaccines: a controversial issue? |
| Q38422886 | HPV-16 infection predicts treatment outcome in oropharyngeal squamous cell carcinoma |
| Q35016793 | High-throughput pseudovirion-based neutralization assay for analysis of natural and vaccine-induced antibodies against human papillomaviruses |
| Q57089326 | Human Papillomavirus Vaccination: Making Sense of the Public Controversy |
| Q47546900 | Human papilloma virus: Apprehending the link with carcinogenesis and unveiling new research avenues (Review). |
| Q54023273 | Human papillomavirus and cervical cancer |
| Q30667372 | Human papillomavirus in high-grade cervical lesions: Austrian data of a European multicentre study |
| Q33622107 | Human papillomavirus infection and cervical cytology in HIV-infected and HIV-uninfected Rwandan women |
| Q37271947 | Human papillomavirus infection and the primary and secondary prevention of cervical cancer. |
| Q35821601 | Human papillomavirus prevalence in South African women and men according to age and human immunodeficiency virus status |
| Q37010572 | Human papillomavirus prevalence in women attending routine cervical screening in South Wales, UK: a cross-sectional study |
| Q51548591 | Human papillomavirus type distribution in vulval intraepithelial neoplasia determined using PapilloCheck DNA Microarray. |
| Q79620675 | Human papillomavirus vaccination: what is the best choice? A comparison of 16 strategies by means of a decisional model |
| Q82710054 | Human papillomavirus vaccine for children and adolescents |
| Q36819424 | Human papillomavirus vaccine uptake among 18- to 26-year-old women in the United States: National Health Interview Survey, 2010 |
| Q37346095 | Human papillomavirus vaccines and vaccine implementation |
| Q35944623 | Human papillomavirus vaccines launch a new era in cervical cancer prevention |
| Q80420441 | Human papillomavirus vaccines to prevent cervical cancer |
| Q37762242 | Human papillomavirus vaccines: current status and future prospects |
| Q38022478 | Human papillomavirus vaccines: where do they fit in HIV-infected individuals? |
| Q51660581 | Human papillomavirus-related gynecologic neoplasms: screening and prevention. |
| Q38136127 | Human papillomavirus: current status and issues of vaccination. |
| Q36486823 | Humoral, mucosal, and cell-mediated immunity against vaccine and nonvaccine genotypes after administration of quadrivalent human papillomavirus vaccine to HIV-infected children |
| Q42273331 | Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model |
| Q40771140 | Immunogenicity and safety of quadrivalent human papillomavirus types 6/11/16/18 recombinant vaccine in chronic kidney disease stage IV, V and VD. |
| Q40767571 | Immunogenicity and safety of the 9-valent HPV vaccine in men. |
| Q35044376 | Immunoprevention of human papillomavirus-associated malignancies |
| Q42368107 | Impact of HPV vaccination: health gains in the Italian female population |
| Q39760748 | Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection |
| Q43655015 | Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women |
| Q45771689 | Incidence of in situ and invasive vulvar cancer in the US, 1998-2003. |
| Q36970255 | Influence of oxidation and multimerization on the immunogenicity of a thioredoxin-l2 prophylactic papillomavirus vaccine |
| Q34078572 | Integrating clinical, community, and policy perspectives on human papillomavirus vaccination |
| Q39807848 | Integrating novel primary- and secondary-prevention strategies: the next challenge for cervical cancer control |
| Q27495979 | Interaction between Chronic Inflammation and Oral HPV Infection in the Etiology of Head and Neck Cancers |
| Q37126067 | Introducing human papillomavirus vaccines - questions remain |
| Q33763951 | Kissing and hpv: honest popular visions, the human papilloma virus, and cancers |
| Q39926058 | Knowledge, attitudes, and communication around human papillomavirus (HPV) vaccination amongst urban Asian mothers and physicians. |
| Q94272324 | Le vaccin contre le virus du papillome humain pour les enfants et les adolescents |
| Q34064235 | Lessons from Australia: human papillomavirus is not a major risk factor for esophageal squamous cell carcinoma |
| Q27013018 | Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins |
| Q37686830 | Long-term cervical cancer prevention strategies across the globe |
| Q55261252 | Loss of chance associated with sub-optimal HPV vaccination coverage rate in France. |
| Q40099782 | Lung carcinomas do not induce T-cell apoptosis via the Fas/Fas ligand pathway but down-regulate CD3 epsilon expression. |
| Q33856453 | Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions |
| Q34777452 | Measuring effectiveness of the cervical cancer vaccine in an Australian setting (the VACCINE study) |
| Q24186582 | Medical and surgical interventions for the treatment of usual-type vulval intraepithelial neoplasia |
| Q97419293 | Metformin inhibits cervical cancer cell proliferation by modulating PI3K/Akt-induced major histocompatibility complex class I-related chain A gene expression |
| Q37299205 | Molecular epidemiology of sexually transmitted human papillomavirus in a self referred group of women in Ireland |
| Q35174433 | Molecular genotyping of human papillomavirus l1 gene in low-risk and high-risk populations in Bangkok |
| Q37222471 | Monitoring HPV vaccination |
| Q34000082 | Murine polyomavirus virus-like particles carrying full-length human PSA protect BALB/c mice from outgrowth of a PSA expressing tumor |
| Q45338163 | Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2. |
| Q37880425 | New approaches to the assessment of vaccine herd protection in clinical trials |
| Q81068254 | New aspects of vulvar cancer: changes in localization and age of onset |
| Q33156844 | New quadrivalent HPV vaccine developments |
| Q93079992 | Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population |
| Q36893209 | Nitric oxide and cancer: a review |
| Q33433442 | Nobel price for vaccination against cervical cancer: current data and guidelines |
| Q49711128 | Non-Vaccine-Type HPV Prevalence after Vaccine Introduction: No Evidence for Type Replacement but Evidence for Cross-Protection |
| Q34730892 | Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine |
| Q80549694 | Papillomavirus vaccines in perspective |
| Q35258843 | Paradigm shifting vaccines: prophylactic vaccines against latent varicella-zoster virus infection and against HPV-associated cancer |
| Q33905022 | Persistent antibodies to HPV virus-like particles following natural infection are protective against subsequent cervicovaginal infection with related and unrelated HPV. |
| Q37777968 | Position paper--HPV and the primary prevention of cancer; improving vaccine uptake by paediatricians |
| Q45884393 | Predictors of parents' willingness to vaccinate for human papillomavirus and physicians' intentions to recommend the vaccine |
| Q33760807 | Prevalence and predictors of high-risk human papillomavirus infection in a population-based sample of women in rural Uganda |
| Q34180553 | Prevalence of human papillomavirus genotypes in HIV-1-infected women in Seattle, USA and Nairobi, Kenya: results from the Women's HIV Interdisciplinary Network (WHIN) |
| Q33396689 | Prevalence of human papillomavirus types 6, 11, 16 and 18 in young Austrian women - baseline data of a phase III vaccine trial |
| Q33761437 | Prevalence, distribution and correlates of endocervical human papillomavirus types in Brazilian women. |
| Q35903261 | Prevention of HPV-related oral cancer: assessing dentists' readiness. |
| Q34272071 | Prevention of cervical, vaginal, and vulval cancers: role of the quadrivalent human papillomavirus (6, 11, 16, 18) recombinant vaccine |
| Q37449048 | Prevention, chemoradiation and surgery for anal cancer. |
| Q38123205 | Prevention, identification and treatment of vulvar squamous (pre)malignancies: a review focusing on quality of care |
| Q37912228 | Primary prophylactic human papillomavirus vaccination programs: future perspective on global impact |
| Q33893024 | Proceedings of the Modeling Evidence in HPV Pre-Conference Workshop in Malmö, Sweden, May 9-10, 2009. |
| Q37241351 | Prophylactic HPV vaccines: new interventions for cancer control |
| Q37658879 | Prophylactic HPV vaccines: the Finnish perspective |
| Q33292779 | Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials |
| Q54217505 | Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. |
| Q37154142 | Prospects and prejudices of human papillomavirus vaccines in India |
| Q37032632 | Protective cancer immunotherapy: what can the innate immune system contribute? |
| Q103825391 | Public health impact and cost-effectiveness of a nine-valent gender-neutral HPV vaccination program in France |
| Q37818140 | Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women |
| Q38229304 | Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil(®)): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts |
| Q24600011 | Randomized controlled trials of interventions to prevent sexually transmitted infections: learning from the past to plan for the future |
| Q34882348 | Recent advances in cancer vaccines: an overview |
| Q47417794 | Reporting of adverse events following immunizations in Ghana – Using disproportionality analysis reporting ratios |
| Q46172480 | Risk perception and sexual behavior in HPV-vaccinated and unvaccinated young Colombian women. |
| Q35875491 | Risk perceptions, sexual attitudes, and sexual behavior after HPV vaccination in 11-12 year-old girls. |
| Q21257274 | Rome Consensus Conference - statement; human papilloma virus diseases in males |
| Q34549645 | Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. |
| Q90656660 | Safety profile of human papilloma virus vaccines: an analysis of the US Vaccine Adverse Event Reporting System from 2007 to 2017 |
| Q33607120 | Severe somatoform and dysautonomic syndromes after HPV vaccination: case series and review of literature. |
| Q80150272 | Sexually transmitted infections |
| Q37518473 | Short version of the German evidence-based Guidelines for prophylactic vaccination against HPV-associated neoplasia |
| Q37553822 | Silencing sexually transmitted infections: topical siRNA-based interventions for the prevention of HIV and HSV |
| Q46093863 | Smoking and multicentric vulval intraepithelial neoplasia |
| Q34096530 | Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates |
| Q35111092 | Systematic review and meta-analysis of L1-VLP-based human papillomavirus vaccine efficacy against anogenital pre-cancer in women with evidence of prior HPV exposure |
| Q21132685 | The aetiological role of human papillomavirus in oesophageal squamous cell carcinoma: a meta-analysis |
| Q92864750 | The impact of p16ink4a positivity in invasive vulvar cancer on disease-free and disease-specific survival, a retrospective study |
| Q36519190 | The implementation and acceptability of an HPV vaccination decision support system directed at both clinicians and families. |
| Q81673065 | The new challenges in the prevention of cervical cancer |
| Q38254337 | The next generation of HPV vaccines: nonavalent vaccine V503 on the horizon |
| Q37395946 | The utility and management of vaginal cytology after treatment for endometrial cancer |
| Q87953041 | US Health Care Clinicians' Knowledge, Attitudes, and Practices Regarding Human Papillomavirus Vaccination: A Qualitative Systematic Review |
| Q37873924 | Understanding the cross-talk between ovarian tumors and immune cells: mechanisms for effective immunotherapies. |
| Q33894441 | Understanding the reasons why mothers do or do not have their adolescent daughters vaccinated against human papillomavirus |
| Q33382208 | Using population-based cancer registry data to assess the burden of human papillomavirus-associated cancers in the United States: overview of methods |
| Q55054088 | Warts (genital). |
| Q33716245 | What do women with gynecologic cancer know about HPV and their individual disease? A pilot study |
| Q37131029 | What's new in dermatologic therapy |
| Q33357138 | What's new in dermatological therapy? |
| Q39824696 | Would the effect of HPV vaccination on non-cervical HPV-positive cancers make the difference for its cost-effectiveness? |
| Q30145640 | Zika virus-like particle (VLP) based vaccine |
| Q80130954 | [Advances in cervical cancer prevention: HPV vaccines] |
| Q79661448 | [HPV vaccination is important for dermatologists] |
| Q43986168 | [Human papillomavirus and cervical neoplasia]. |
| Q52340945 | [Researcher of the month, October 2012]. |
| Q81732655 | [What's new in medicine in 2007?] |
Search more.